Vanguard Group Inc. lessened its position in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 3.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 3,506,287 shares of the biopharmaceutical company's stock after selling 125,002 shares during the period. Vanguard Group Inc. owned approximately 6.01% of Vanda Pharmaceuticals worth $16,795,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds have also bought and sold shares of the company. FMR LLC grew its position in Vanda Pharmaceuticals by 25.9% during the third quarter. FMR LLC now owns 149,739 shares of the biopharmaceutical company's stock worth $702,000 after buying an additional 30,802 shares in the last quarter. Barclays PLC increased its position in shares of Vanda Pharmaceuticals by 128.2% in the third quarter. Barclays PLC now owns 154,297 shares of the biopharmaceutical company's stock worth $722,000 after purchasing an additional 86,677 shares during the last quarter. JPMorgan Chase & Co. raised its stake in Vanda Pharmaceuticals by 16.1% in the third quarter. JPMorgan Chase & Co. now owns 160,722 shares of the biopharmaceutical company's stock valued at $754,000 after purchasing an additional 22,249 shares in the last quarter. Geode Capital Management LLC lifted its position in Vanda Pharmaceuticals by 7.1% during the third quarter. Geode Capital Management LLC now owns 1,425,827 shares of the biopharmaceutical company's stock valued at $6,689,000 after purchasing an additional 94,870 shares during the last quarter. Finally, SG Americas Securities LLC grew its stake in Vanda Pharmaceuticals by 26.8% in the 4th quarter. SG Americas Securities LLC now owns 25,861 shares of the biopharmaceutical company's stock worth $124,000 after buying an additional 5,459 shares in the last quarter. 88.14% of the stock is currently owned by hedge funds and other institutional investors.
Vanda Pharmaceuticals Stock Down 0.9 %
Shares of NASDAQ:VNDA traded down $0.04 during midday trading on Friday, reaching $4.33. The company's stock had a trading volume of 506,632 shares, compared to its average volume of 790,125. The firm has a market capitalization of $252.51 million, a P/E ratio of -13.53 and a beta of 0.72. Vanda Pharmaceuticals Inc. has a 12-month low of $3.85 and a 12-month high of $6.75. The firm has a 50 day moving average of $4.59 and a 200-day moving average of $4.68.
Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last issued its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.06. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%. The company had revenue of $53.19 million for the quarter, compared to analysts' expectations of $51.00 million. On average, research analysts predict that Vanda Pharmaceuticals Inc. will post -1.12 EPS for the current year.
Analysts Set New Price Targets
VNDA has been the subject of several research analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $20.00 price target on shares of Vanda Pharmaceuticals in a research note on Tuesday, April 1st. StockNews.com began coverage on Vanda Pharmaceuticals in a research note on Wednesday, February 5th. They issued a "hold" rating on the stock.
Read Our Latest Research Report on VNDA
Insider Transactions at Vanda Pharmaceuticals
In other news, CEO Mihael Hristos Polymeropoulos bought 10,000 shares of the firm's stock in a transaction on Friday, February 28th. The shares were bought at an average price of $4.76 per share, for a total transaction of $47,600.00. Following the purchase, the chief executive officer now owns 2,361,730 shares in the company, valued at approximately $11,241,834.80. The trade was a 0.43 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders purchased 32,000 shares of company stock worth $151,180 in the last three months. Corporate insiders own 8.90% of the company's stock.
Vanda Pharmaceuticals Company Profile
(
Free Report)
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.
Recommended Stories
Before you consider Vanda Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vanda Pharmaceuticals wasn't on the list.
While Vanda Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
